Emanuelli Research and Development Center, LLC

Arecibo 612

1 studies enrolling now · 12 studies all time

What they study most

Age-Related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Geographic Atrophy Secondary to Age-related Macular Degeneration, Macular Degeneration, Neovascular Age-related Macular Degeneration, Proliferative Diabetic Retinopathy

Studies at this site

• A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema — Completed
• An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration — Running, not enrolling
• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema — Running, not enrolling
• A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
• Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration — Running, not enrolling
• Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy — Completed
• A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema — Completed
• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration — Running, not enrolling
• Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial — Completed
• A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy — Completed